Severe COVID-19 Shares a Common Neutrophil Activation Signature with Other Acute Inflammatory States

Lena F Schimke1, Alexandre H C Marques1, Gabriela Crispim Baiocchi1

  • 1Department of Imunology, Institute of Biomedical Sciences, University of São Paulo, São Paulo 05508-000, Brazil.

Cells
|March 10, 2022
PubMed

Insights

Severe COVID-19 shares inflammatory pathways with hemophagocytic lymphohistiocytosis (HLH). Neutrophil-associated genes strongly correlate with severe COVID-19, suggesting new therapeutic targets.

Area of Science:

  • Immunology
  • Genomics
  • Computational Biology

Background:

  • Severe COVID-19 exhibits clinical overlap with hyperinflammatory conditions like hemophagocytic lymphohistiocytosis (HLH).
  • Underlying mechanisms driving this overlap require further investigation.

Purpose of the Study:

  • To investigate the shared immunological and genetic mechanisms between severe COVID-19 and other hyperinflammatory states.
  • To identify potential therapeutic targets for severe COVID-19 by analyzing transcriptomic data.

Main Methods:

  • Transcriptome analysis of 1596 individuals, including COVID-19 patients, HLH, MIS-C, KD, and other respiratory infections.
  • Differential gene expression analysis, protein-protein interaction network analysis, single-cell RNA sequencing (scRNAseq), and artificial intelligence modeling.

Main Results:

  • COVID-19 and HLH share key immunological pathways, including cytokine/chemokine signaling and neutrophil-mediated immune responses.
  • A distinct gene signature, particularly neutrophil-associated genes, stratifies severe COVID-19 patients and is also observed in Kawasaki disease and bacterial pneumonia.
  • These neutrophil-associated genes are upregulated in leukocytes, dysregulated at the protein level, and strongly linked to COVID-19 severity via AI modeling.

Conclusions:

  • Shared neutrophil hyperactivation pathways contribute to severe COVID-19 and other hyperinflammatory conditions.
  • Neutrophil-associated gene signatures represent potential biomarkers for COVID-19 severity.
  • Identified pathways offer novel therapeutic strategies for severe COVID-19 intervention.